BETHESDA, Md. & ABBOTT PARK, Ill.--(BUSINESS WIRE)-- Sucampo Pharmaceuticals, Inc. (“Sucampo”) (NASDAQ: SCMP) and Abbott (NYSE: ABT) today reported data from a phase 3 clinical efficacy trial in 124 ...
Professor Takaaki Abe and his team discovered that a medicine called lubiprostone, which is normally used to treat ...
Progenics could receive $20 million in milestones. Ono Pharmaceutical is paying $15 million for rights to develop Progenics Pharmaceuticals’ opioid-induced constipation drug, Relistor®, in Japan.
When a phase two clinical trial from Japan suggested that a common constipation medicine might slow the progression of ...
Sucampo Pharma, Ltd., a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. (SPI) has received approval from the Ministry of Health, Labor and Welfare in Japan for Amitiza (lubiprostone), a ...
A surprising link between constipation and kidney decline led researchers to test lubiprostone, revealing that it can protect kidney function. The results point toward gut-based, mitochondria-boosting ...
A Japanese study suggests that lubiprostone, a common constipation drug, may help slow kidney decline in people with chronic ...
Sweden's Albireo has reached a licensing deal with a Japanese drugmaker, giving Ajinomoto Pharmaceuticals the rights to develop and market a constipation drug in Japan, South Korea, Thailand, ...
A common constipation drug, lubiprostone, shows remarkable potential in slowing kidney function decline for chronic kidney ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback